Last reviewed · How we verify
Atropine Sulfate 02
Atropine sulfate is an anticholinergic agent that blocks muscarinic acetylcholine receptors to inhibit parasympathetic nervous system activity.
Atropine sulfate is an anticholinergic agent that blocks muscarinic acetylcholine receptors to inhibit parasympathetic nervous system activity. Used for Anticholinergic poisoning and organophosphate/nerve agent exposure, Symptomatic bradycardia, Mydriasis and cycloplegia for ophthalmic examination.
At a glance
| Generic name | Atropine Sulfate 02 |
|---|---|
| Also known as | LPTAT02 |
| Sponsor | LitePharmTech Co., Ltd. |
| Drug class | Anticholinergic agent / Muscarinic receptor antagonist |
| Target | Muscarinic acetylcholine receptors (M1-M5) |
| Modality | Small molecule |
| Therapeutic area | Emergency Medicine, Ophthalmology, Cardiology |
| Phase | Phase 3 |
Mechanism of action
Atropine competitively antagonizes acetylcholine at muscarinic receptors throughout the body, reducing parasympathetic effects on the heart, smooth muscle, and secretory glands. This results in increased heart rate, bronchodilation, decreased secretions, and mydriasis. The sulfate salt formulation enhances solubility and bioavailability for parenteral or oral administration.
Approved indications
- Anticholinergic poisoning and organophosphate/nerve agent exposure
- Symptomatic bradycardia
- Mydriasis and cycloplegia for ophthalmic examination
- Preoperative antisialagogue
Common side effects
- Tachycardia
- Dry mouth
- Mydriasis and cycloplegia
- Urinary retention
- Constipation
- Confusion or agitation (at high doses)
- Hyperthermia
Key clinical trials
- Using Diaphragm Ultrasonography, Sugammadex Recovers Diaphragmatic Function More Effectively Than Neostigmine. (PHASE1)
- Study of Atropine Therapeutic Effect on Myopic Progression (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atropine Sulfate 02 CI brief — competitive landscape report
- Atropine Sulfate 02 updates RSS · CI watch RSS
- LitePharmTech Co., Ltd. portfolio CI